<DOC>
	<DOCNO>NCT00094822</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness Neulasta® ( pegfilgrastim ) reduce infection give day versus one day completion chemotherapy ( docetaxel carboplatin ) patient advanced metastatic non-small cell lung cancer ( NSCLC ) . This study consider `` investigational '' previous study Neulasta® use next day dose day dosing .</brief_summary>
	<brief_title>Pegfilgrastim Given Same Day As Day After Carboplatin Docetaxel Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Eligibility Criteria : Age 18 year old Diagnosis advance metastatic nonsmall cell lung cancer ( NSCLC ) Have receive prior chemotherapy Have receive radiation therapy undergone major surgery within past 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Neulasta®</keyword>
	<keyword>pegfilgrastim</keyword>
</DOC>